GCKR rs12602861: Fasting Lipids and Glucose Regulation
The genetic variant rs12602861 is located in the glucokinase regulator (GCKR) gene, which plays a central role in hepatic energy processing. Genome-wide analyses link this locus to variations in fasting blood triglyceride concentrations and circulating glucose levels. The variant reflects a common metabolic trade-off in the liver between carbohydrate disposal and lipid synthesis.
What each genotype means
Baseline metabolic profile
This genotype represents the major allele combination for this variant. Research indicates that individuals with this profile typically exhibit higher fasting blood glucose levels and lower fasting triglyceride levels compared to those carrying the T allele.
This is the most common genotype, found in the majority of individuals across most global populations.
Intermediate metabolic association
Carrying one copy of the T allele is associated with a shift in metabolic markers, specifically tending toward lower fasting blood glucose and higher fasting triglyceride levels. These associations are statistical observations in large populations and do not constitute a medical diagnosis.
This heterozygous genotype is very common, appearing in a significant portion of the global population.
Altered metabolic association
Individuals with this genotype carry two copies of the T allele, which is associated with the most pronounced effect on fasting blood glucose and triglyceride levels. Research suggests this variant influences glucokinase regulation in the liver, though these effects are complex and influenced by other lifestyle and genetic factors.
This genotype is present in a substantial minority of the population, with frequencies varying by ancestry.
Genomic Context and the GCKR Locus
The single nucleotide polymorphism rs12602861 sits within the human GCKR gene on chromosome 2. This gene encodes glucokinase regulatory protein (GKRP), an essential regulator of glucose storage and processing in hepatocytes. In population genetics, variants in the GCKR locus are frequently studied in close linkage with nearby functional polymorphisms, such as the well-characterized missense substitution rs1260326 (P446L). While the rs12602861 variant itself is cataloged primarily as a non-coding or proxy marker, its genomic location places it in direct proximity to key regulatory sequences governing how GKRP expression responds to fluctuating cellular nutrients. Variations across this chromosomal segment consistently show statistical relationships with quantitative blood metabolites involved in systemic energy balance.
Biological Role of Glucokinase Regulatory Protein
In the human liver, glucokinase (GCK) acts as the primary sensor and initial gatekeeper for carbohydrate metabolism, phosphorylating glucose into glucose-6-phosphate. The regulatory partner GKRP dynamically modulates this enzymatic activity by sequestering glucokinase inside the cell nucleus when circulating glucose concentrations are low. When blood glucose or dietary fructose concentrations rise, GKRP releases glucokinase to the cytoplasm to rapidly drive glycolysis and glycogen synthesis. Genetic variants within GCKR can subtly impair or alter this molecular latching mechanism. Altered GKRP-GCK interaction shifts the balance of hepatic substrate routing, simultaneously lowering blood sugar while promoting the conversion of surplus metabolic intermediates into fatty acids and triglycerides.
Research Associations and Evidence Strength
Large-scale genome-wide association studies (GWAS) and metabolic profiling cohorts have repeatedly documented an inverse relationship between fasting glucose and circulating lipid parameters at the GCKR locus. The presence of the alternative allele is statistically associated with modest elevations in fasting serum triglycerides and very-low-density lipoproteins, alongside slight decreases in fasting blood glucose and reduced markers of insulin resistance. However, the direct clinical evidence for rs12602861 specifically is classified as limited in isolation, largely because its observed biological effects are shared across a broader haplotype block encompassing several tightly linked GCKR markers. Observed effect sizes for individual SNPs at this locus are modest, showing population-level shifts rather than decisive single-gene clinical outcomes.
Distribution Across Populations
Allelic variation at rs12602861 is common across human ancestral backgrounds. Aggregated reference datasets such as the Genome Aggregation Database (gnomAD) report a minor allele frequency typically spanning between 0.35 and 0.45 across major global populations. Both the reference and alternate alleles are well represented in European, East Asian, South Asian, African, and American cohorts, although precise frequencies show slight regional variation. Because neither allele is rare or pathogenic on its own, this variant represents typical polygenic variation naturally maintained within the human gene pool rather than an inherited disease mutation.
Interpreting Results and Clinical Perspective
Having particular alleles at rs12602861 does not diagnose hypertriglyceridemia, diabetes, or metabolic disease, nor does it guarantee altered laboratory markers. Because quantitative metabolic traits are polygenic, individual genetic variations contribute only a minor fraction toward overall blood lipid and glucose measurements. Daily diet, physical activity, body composition, and medication choices exert far greater influence on cardiovascular risk and metabolic health. Genetic results from this locus cannot be used to start, alter, or discontinue any medical treatments. Individuals concerned about their fasting triglycerides or glucose levels should review standard diagnostic blood panels directly with their personal healthcare provider.
How common is this variant?
The minor allele frequency for rs12602861 ranges between approximately 0.35 and 0.45 across diverse global populations in gnomAD. Because both alleles are widespread, heterozygous and homozygous genotypes are commonly encountered across multiple ancestral groups.
Frequently asked questions
What is the rs12602861 variant?
The rs12602861 variant is a common single nucleotide polymorphism located in the GCKR gene on chromosome 2. It is studied for its association with hepatic glucokinase activity and subtle shifts in blood lipid and glucose levels.
Does having this variant mean I will get high triglycerides?
No, carrying the variant allele does not mean you will develop clinically high triglycerides. It is associated with small statistical differences across large study groups, but overall lipid levels are primarily governed by lifestyle, diet, and polygenic factors.
How does the GCKR gene affect blood sugar and lipids simultaneously?
GCKR produces a regulatory protein that controls glucokinase in liver cells. When glucokinase activity is enhanced or deregulated, the liver clears glucose more rapidly from circulation, but that excess carbon can be channeled directly into the production of fatty acids and triglycerides.
Can I use my rs12602861 genotype to adjust my medications?
No, genotype information from this variant should never be used to initiate, stop, or adjust prescription medications. Any decisions regarding lipid-lowering therapies or diabetes medications should be made in consultation with a qualified clinician.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12602861?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in GCKR
A significant SNP identified through fine-mapping that demonstrates a consistent effect on triglyceride levels across different ancestral populations.
A well-replicated regulatory/intronic variant within GCKR strongly associated with variation in fasting serum triglycerides, glucose levels, and lipid metabolism.
GCKR P446L modulates the glucokinase regulatory protein and balances triglyceride and glucose levels.
This variant is associated with variations in fasting glucose and lipid levels, commonly studied in metabolic GWAS.
This variant in the glucokinase regulator (GCKR) locus is significantly associated with altered fasting plasma glucose, serum triglyceride levels, and hepatic fat accumulation.